Protocols›Performance & endurance›Strongman / Powerlifting
← Protocols
Athlete / performance · uptakeCommunity · convergenceNo approved clinical use

Strongman / Powerlifting

Stack: BPC-157 + TB-500 + MGF + IGF-1 LR3 · strength recovery / output
"A maximal-strength recovery/output stack that adds IGF-1 LR3 — the point where 'community reference' meets real risk. Weak human evidence, presented as information only."
GoalStrength recovery / output
Compounds4 · BPC-157 + TB-500 + MGF + IGF-1 LR3
Humans exposed (est.)Moderate — undocumented
StatusMHRA (UK): not licensed medicines here · FDA (US): not approved · IGF-1 LR3 carries real risk
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Athlete / performance
Where / who
Community / athlete and clinic use as tagged above.
Use status
Used in strength circles.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
BPC-157 / TB-500: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing; removed from Category 2 Apr 2026, 503A Bulks List decision pending the PCAC meeting 23–24 Jul 2026.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Weak/absent human evidence; IGF-1 LR3 risk.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Why this combination

The repair pair plus MGF and IGF-1 LR3 for direct anabolic intent. IGF-1 LR3 carries a real risk profile and has no human efficacy trials for this use. This is documented as community reference, not endorsement.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Get TiQ1 · Free →
Free · just create an account
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Moderate

Used in strength circles.

Human efficacy None

Weak/absent human evidence; IGF-1 LR3 risk.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Higher risk, not higher evidence.

Fast facts
Compounds

BPC-157 · TB-500 · MGF · IGF-1 LR3

Humans exposed (est.)

Moderate — undocumented.

UK strip

GREEN — research material